Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of ...

Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing.

MSK orthopedic surgeon Dr. Jonathan Forsberg examines Michelle Smith-Levitin’s leg at a follow-up appointment — a first-of-its-kind surgical implant saved her leg. The tennis court was Michelle ...

1 Department of Orthopedics, Orthopaedic Research Institute, West China Hospital, Sichuan University, Chengdu, China 2 Bone and Joint 3D-Printing and Biomechanical Laboratory, Department of ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...

At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

Glioblastoma (GBM) is an aggressive and common brain cancer in adults with average life expectancies of 12–18 months after diagnosis and median survival rate for recurrent GBM ranging from 6–10 months ...

Patients with tenosynovial giant cell tumor can take some comfort in knowing that this rare type of tumor affecting joints won’t kill them. But that doesn’t make living with the disease easy. Merck ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER ...

Merck KGaA said pimicotinib, an orally administered inhibitor for tenosynovial giant cell tumor, delivered positive results in a late-phase study. The German life-sciences and electronics company said ...